Pacer Advisors
CRNX icon

Pacer Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Pacer Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-638
Closed -$28.6K – 2593
2024
Q2 		$28.6K Sell
638
-373
-37% -$17.2K ﹤0.01% 3355
2024
Q1 		$47.3K Buy
+1,011
New +$39.6K ﹤0.01% 3192

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Pacer Advisors's CRNX Position: Q3 2024 in Review

Pacer Advisors sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2024, closing a stake of 638 shares — an estimated $28.6K sold.

Pacer Advisors first reported a position in CRNX in Q1 2024 and held it in 2 quarters. The position peaked at $47.3K in Q1 2024. 235 funds tracked by Wall St. Rank hold CRNX as of Q3 2024.

  • Pacer Advisors reported no remaining Crinetics Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 638 Crinetics Pharmaceuticals shares in Q3 2024, an estimated $28.6K.
  • Pacer Advisors first reported a position in Crinetics Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Pacer Advisors's Crinetics Pharmaceuticals position peaked at $47.3K in Q1 2024.
  • 235 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.